TCS JNK 5a (also known as JNK Inhibitor IX; TCS JNK-5a) is a novel, highly selective and potent JNK (c-Jun N-terminal Kinase) inhibitor with potential antineoplastic activity.

SP600125 (SP6-00125; NSC-75890) is a cell-permeable, broad-spectrum, reversible and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with potential anticancer and anti-inflammatory activity.

AS601245 is an inhibitor of the JNK signaling pathway, it showed high JNK1/2/3 inhibition with IC50 of 150, 220, and 70 nM respectively.

CC-401 HCl (CC401 hydrochloride) is an anthrapyrazolone-based inhibitor of c-Jun N terminal kinase (JNK) with potential anticancer activity.

JNK Inhibitor VIII (TCS JNK 6o) is a selective and ATP-competitive inhibitor of c-Jun N-terminal kinases (JNK-1, -2, and -3) with Kis of 2 nM, 4 nM, 52 nM, respectively, and has IC50 of 45 nM and 160 nM for JNK-1 and -2, respectively.

CC-90001 (CC90001; CC 90001) is a novel, potent and selective inhibitor of c-Jun N-terminal kinase (JNK) with potential anti-fibrotic activity.

BI-78D3 (also known as JNK Inhibitor X) is a novel, potent and competitive JNK inhibitor with IC50 of 280nM.

Loureirin B is a novel and potent bioactive compound.

DTP3 (DTP-3) is a novel, potent and selective inhibitor of GADD45β/MKK7 ((growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) with potential anticancer activity.

AEG-3482 is a novel and potent antiapoptotic compound.